Geode Capital Management LLC increased its position in shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) by 10.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 121,532 shares of the company’s stock after buying an additional 11,035 shares during the period. Geode Capital Management LLC’s holdings in Aquinox Pharmaceuticals were worth $2,028,000 as of its most recent filing with the SEC.

Shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) traded down 0.14% during midday trading on Tuesday, reaching $14.70. 13,809 shares of the company’s stock traded hands. Aquinox Pharmaceuticals, Inc. has a 52 week low of $9.23 and a 52 week high of $19.97. The stock’s 50 day moving average is $14.46 and its 200-day moving average is $15.18. The company’s market capitalization is $344.92 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Tuesday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.59). On average, analysts forecast that Aquinox Pharmaceuticals, Inc. will post ($2.15) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/aquinox-pharmaceuticals-inc-aqxp-shares-bought-by-geode-capital-management-llc/1530062.html.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Canaccord Genuity set a $22.00 price target on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 8th. BidaskClub raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Cantor Fitzgerald set a $28.00 price target on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 9th. Finally, ValuEngine raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $22.25.

In other news, insider David Main sold 15,625 shares of Aquinox Pharmaceuticals stock in a transaction on Monday, June 5th. The stock was sold at an average price of $13.26, for a total transaction of $207,187.50. Following the transaction, the insider now owns 77,530 shares in the company, valued at $1,028,047.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.70% of the company’s stock.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Institutional Ownership by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.